Semaglutide Generics Price
-
{
- All
- News
-
Dr Reddy's Wins Nod to Sell Generic Ozempic, Check Cost Of Weight-Loss Drug
- Wednesday April 29, 2026
- India News | Edited by Prateek Shukla
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
-
www.ndtv.com
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
- Wednesday March 25, 2026
- Health | Written by Varsha Vats
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
www.ndtv.com
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
- Tuesday March 24, 2026
- Health | Indo-Asian News Service
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
www.ndtv.com
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
- Monday March 23, 2026
- Health | Written by Shreya Goswami
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
www.ndtv.com
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
- Saturday March 21, 2026
- Health | Reported by Tanushka Dutta
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
- Sunday March 22, 2026
- Health | Written by Dr Kona Lakshmi Kumari
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
www.ndtv.com
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
- Friday March 20, 2026
- Health | Written by Dr Hari Kishan Boorugu
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
www.ndtv.com
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
- Thursday March 19, 2026
- Health | Written by Sambhav Kumar
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
www.ndtv.com
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
- Thursday March 19, 2026
- Health | Reported by Tanushka Dutta
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
www.ndtv.com
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
- Thursday March 19, 2026
- Health | Written by Dr Kona Lakshmi Kumari
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
www.ndtv.com
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
- Wednesday March 18, 2026
- Health | Written by Shreya Goswami
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
www.ndtv.com
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
- Tuesday March 17, 2026
- Health | Written by Sambhav Kumar
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
www.ndtv.com
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
- Monday March 16, 2026
- Health | Written by Sambhav Kumar
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
www.ndtv.com
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
- Wednesday March 18, 2026
- Health | Satviki Sanjay, Bloomberg
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
www.ndtv.com
-
Dr Reddy's Wins Nod to Sell Generic Ozempic, Check Cost Of Weight-Loss Drug
- Wednesday April 29, 2026
- India News | Edited by Prateek Shukla
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
-
www.ndtv.com
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
- Wednesday March 25, 2026
- Health | Written by Varsha Vats
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
www.ndtv.com
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
- Tuesday March 24, 2026
- Health | Indo-Asian News Service
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
www.ndtv.com
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
- Monday March 23, 2026
- Health | Written by Shreya Goswami
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
www.ndtv.com
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
- Saturday March 21, 2026
- Health | Reported by Tanushka Dutta
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
- Sunday March 22, 2026
- Health | Written by Dr Kona Lakshmi Kumari
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
www.ndtv.com
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
- Friday March 20, 2026
- Health | Written by Dr Hari Kishan Boorugu
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
www.ndtv.com
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
- Thursday March 19, 2026
- Health | Written by Sambhav Kumar
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
www.ndtv.com
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
- Thursday March 19, 2026
- Health | Reported by Tanushka Dutta
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
www.ndtv.com
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
- Thursday March 19, 2026
- Health | Written by Dr Kona Lakshmi Kumari
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
www.ndtv.com
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
- Wednesday March 18, 2026
- Health | Written by Shreya Goswami
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
www.ndtv.com
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
- Tuesday March 17, 2026
- Health | Written by Sambhav Kumar
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
www.ndtv.com
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
- Monday March 16, 2026
- Health | Written by Sambhav Kumar
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
www.ndtv.com
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
- Wednesday March 18, 2026
- Health | Satviki Sanjay, Bloomberg
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
www.ndtv.com